Cutaneous And Systemic Leishmaniasis Market Size, Share and Forecast 2026
The Cutaneous and systemic leishmaniasis market is expected to grow at a CAGR of XX% during the forecast period 2019-2026.
(EMAILWIRE.COM, September 13, 2019 ) Market Overview:
Cutaneous leishmaniasis is also known as oriental sore, tropical sore, Aleppo boil, Delhi Boil or desert boil. It is the most common form of leishmaniasis affecting humans. The cutaneous form presents with skin ulcers. It is a skin infection caused by a single-celled parasite that is transmitted by the bite of a phlebotomine sandfly. There are about twenty species of Leishmania that cause cutaneous leishmaniasis.
Market Dynamics:
Research and development by prominent manufacturers of this market to introduce new drugs into the market, which are more effective as well as affordable is the key factor driving the global cutaneous and systemic leishmaniasis market.
However, the treatment for cutaneous and systemic leishmaniasis is very expensive and can cause serious adverse effects such as vomiting, nausea, anorexia, myalgia, abdominal pain, headache, arthralgia, and lethargy and can rarely cause the severe reaction of fatal cardiac arrhythmia. These factors are hampering the global cutaneous and systemic leishmaniasis market growth.
Market Segmentation:
By Drug Class
• Pentavalent Antimonials
• Anti-fungal Drugs
• Antimicrobial / Anti-leishmanial
By Route of Administration
• Oral
• Topical
• Injections
By Indication
• Cutaneous leishmaniasis
• Mucosal leishmaniasis
• Visceral leishmaniasis
By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
Geographical Analysis:
By Geography, the market is segmented into:
• North America
• Europe
• South America
• Asia Pacific
• The Middle East and Africa
Competitive Analysis:
Key Players:
• GlaxoSmithKline Plc.*
• Gilead Sciences, Inc.
• Profounda Pharmaceuticals
• Knight Therapeutics Inc.
• Janssen Global Services, LLC
• Albert David Ltd
• Others
View full report: https://www.datamintelligence.com/research-report/cutaneous-and-systemic-leishmaniasis-market
Download free sample: https://www.datamintelligence.com/download-sample/cutaneous-and-systemic-leishmaniasis-market
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Cutaneous leishmaniasis is also known as oriental sore, tropical sore, Aleppo boil, Delhi Boil or desert boil. It is the most common form of leishmaniasis affecting humans. The cutaneous form presents with skin ulcers. It is a skin infection caused by a single-celled parasite that is transmitted by the bite of a phlebotomine sandfly. There are about twenty species of Leishmania that cause cutaneous leishmaniasis.
Market Dynamics:
Research and development by prominent manufacturers of this market to introduce new drugs into the market, which are more effective as well as affordable is the key factor driving the global cutaneous and systemic leishmaniasis market.
However, the treatment for cutaneous and systemic leishmaniasis is very expensive and can cause serious adverse effects such as vomiting, nausea, anorexia, myalgia, abdominal pain, headache, arthralgia, and lethargy and can rarely cause the severe reaction of fatal cardiac arrhythmia. These factors are hampering the global cutaneous and systemic leishmaniasis market growth.
Market Segmentation:
By Drug Class
• Pentavalent Antimonials
• Anti-fungal Drugs
• Antimicrobial / Anti-leishmanial
By Route of Administration
• Oral
• Topical
• Injections
By Indication
• Cutaneous leishmaniasis
• Mucosal leishmaniasis
• Visceral leishmaniasis
By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
Geographical Analysis:
By Geography, the market is segmented into:
• North America
• Europe
• South America
• Asia Pacific
• The Middle East and Africa
Competitive Analysis:
Key Players:
• GlaxoSmithKline Plc.*
• Gilead Sciences, Inc.
• Profounda Pharmaceuticals
• Knight Therapeutics Inc.
• Janssen Global Services, LLC
• Albert David Ltd
• Others
View full report: https://www.datamintelligence.com/research-report/cutaneous-and-systemic-leishmaniasis-market
Download free sample: https://www.datamintelligence.com/download-sample/cutaneous-and-systemic-leishmaniasis-market
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results